Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001877128 | SCV002133183 | uncertain significance | not provided | 2021-09-28 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. This variant has not been reported in the literature in individuals affected with PLXNA1-related conditions. This variant is present in population databases (rs149382163, ExAC 0.04%). This sequence change replaces arginine with leucine at codon 453 of the PLXNA1 protein (p.Arg453Leu). The arginine residue is moderately conserved and there is a moderate physicochemical difference between arginine and leucine. |
Ambry Genetics | RCV004040498 | SCV003572834 | uncertain significance | not specified | 2021-08-13 | criteria provided, single submitter | clinical testing | The c.1358G>T (p.R453L) alteration is located in exon 2 (coding exon 2) of the PLXNA1 gene. This alteration results from a G to T substitution at nucleotide position 1358, causing the arginine (R) at amino acid position 453 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |